Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.
This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Recent growth in health care spending for commercially insured individuals is due primarily to increases in prices for medical services, rather than increased use, according to a new study led by researchers at The Dartmouth Institute for Health Policy & Clinical Practice, published today in the American Journal of Managed Care.
The race will feature a Republican turned Democrat against a one-time supporter of Medicaid expansion who now isn’t so sure. But this much is certain: in Florida’s race for governor, health care will take center stage, as former Gov. Charlie Crist tries to unseat incumbent Gov. Rick Scott.
If anyone thought Myriad Genetics’ legal battles were over when it lost at the US Supreme Court in 2013, that person would be wrong. In many ways, the ruling in Association for Molecular Pathology v. Myriad Genetics, which found that a naturally occurring DNA sequence cannot be patented, was just the beginning for the Salt Lake City-based testing company.
The American Journal of Managed Care’s ACO Coalition, now at 100 members, gives healthcare leaders a way to share ideas for improving population health. A recent Web-based exchange involving Mount Sinai ACO’s diabetes strategy showed how the initiative is working to spread good ideas across the country.